Journal of Neuroimmunology
Volume 215, Issue 1 , Pages 108-116 , 30 October 2009

Effects of interferon-beta therapy on innate and adaptive immune responses to the human endogenous retroviruses HERV-H and HERV-W, cytokine production, and the lectin complement activation pathway in multiple sclerosis

  • Thor Petersen

      Affiliations

    • Department of Neurology, Aarhus University Hospital, Nørrebrogade 44, DK-8000 Aarhus C, Denmark
    • ,
  • Anné Møller-Larsen

      Affiliations

    • Institute of Medical Microbiology and Immunology, Bartholin Building, University of Aarhus, DK-8000 Aarhus C, Denmark
    • ,
  • Steffen Thiel

      Affiliations

    • Institute of Medical Microbiology and Immunology, Bartholin Building, University of Aarhus, DK-8000 Aarhus C, Denmark
    • ,
  • Tomasz Brudek

      Affiliations

    • Institute of Medical Microbiology and Immunology, Bartholin Building, University of Aarhus, DK-8000 Aarhus C, Denmark
    • ,
  • Troels Krarup Hansen

      Affiliations

    • Immunoendocrine Research Unit, Medical Department M (Diabetes and Endocrinology) and Medical Research Laboratories, Clinical Institute, Aarhus University Hospital, Aarhus, Denmark
    • ,
  • Tove Christensen

      Affiliations

    • Institute of Medical Microbiology and Immunology, Bartholin Building, University of Aarhus, DK-8000 Aarhus C, Denmark
    • Corresponding Author InformationCorresponding author.

Received 6 July 2009 ,Revised 26 August 2009 ,Accepted 28 August 2009.

References 

  1. Antony JM, Van Marle G, Opii W, Butterfield DA, Mallet F, Yong VW, et al. Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat. Neurosci. 2004;7:1088–1095
  2. Bangham C. HTLV-1 infections. J. Clin. Pathol. 2000;53:581–586
  3. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 2004;55:458–468
  4. Baron S, Tyring SK, Fleischmann WR, Coppenhaver DH, Niesel DW, Klimpel GR, et al. The interferons. Mechanisms of action and clinical applications. JAMA. 1991;266:1375–1383
  5. Berger T, Reindl M. Multiple sclerosis: disease biomarkers as indicated by pathophysiology. J. Neurol. Sci. 2007;259:21–26
  6. Blond JL, Beseme F, Duret L, Bouton O, Bedin F, Perron H, et al. Molecular characterization and placental expression of HERV-W, a new human endogenous retrovirus family. J. Virol. 1999;73:1175–1185
  7. Burbelo PD, Meoli E, Leahy HP, Graham J, Yao K, Oh U, et al. Anti-HTLV antibody profiling reveals an antibody signature for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology. 2008;5:96
  8. Carrieri PB, Ladogana P, Di Spigna G, de Leva MF, Petracca M, Montella S, et al. Interleukin-10 and interleukin-12 modulation in patients with relapsing–remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders. Immunopharmacol. Immunotoxicol. 2008;30:1–9
  9. Christensen T. Association of human endogenous retroviruses with multiple sclerosis and possible interactions with herpes viruses. Rev. Med. Virol. 2005;15:179–211
  10. Christensen T. Retroviruses in autoimmunity. In:  Pandalai SG editors. Recent Research Developments in Immunology. vol. 7:Kerala: Research Signpost; 2006;p. 25–43
  11. Christensen T, Møller-Larsen A, Haahr S. A retroviral implication in multiple sclerosis?. Trends Microbiol. 1994;2:332–336
  12. Christensen T, Dissing Sørensen P, Hansen HJ, Møller-Larsen A. Antibodies against a human endogenous retrovirus and the preponderance of env splice variants in multiple sclerosis patients. Mult. Scler. 2003;9:6–15
  13. Christensen T, Petersen T, Thiel S, Brudek T, Ellermann-Eriksen E, Møller-Larsen A. Gene–environment interactions in multiple sclerosis: innate and adaptive immune responses to human endogenous retrovirus and herpes virus antigens and the lectin complement activation pathway. J. Neuroimmunol. 2007;183:175–188
  14. Christiansen OB, Kilpatrick DC, Souter V, Varming K, Thiel S, Jensenius JC. Mannose-binding lectin deficiency is associated with unexplained recurrent miscarriage. Scand. J. Immunol. 1999;49:193–196
  15. Comabella M, Río J, Espejo C, Ruiz de Villa M, Al-Zayat H, Nos C, et al. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clin. Immunol. 2009;130:145–150
  16. Dahl MR, Thiel S, Matsushita M, Fujita T, Willis AC, Christensen T, et al. MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity. 2001;15:127–135
  17. de Parseval N, Lazar V, Casella JF, Benit L, Heidmann T. Survey of human genes of retroviral origin: identification and transcriptome of the genes with coding capacity for complete envelope proteins. J. Virol. 2003;77:10414–10422
  18. Fernald GH, Knott S, Pachner A, Caillier SJ, Narayan K, Oksenberg JR, et al. Genome-wide network analysis reveals the global properties of IFN-beta immediate transcriptional effects in humans. J. Immunol. 2007;178:5076–5085
  19. Filippi M, Rocca MA. MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. J. Neurol. 2005;252(S5):16–24
  20. Francis G, Weber F, Rieckmann P. Effect of interferon beta on human myelin basic protein-specific T-cell lines: comparison of IFNbeta-1a and IFNbeta-1b. Neurology. 2000;55:322–323
  21. Funding M, Hansen TK, Gjedsted J, Ehlers N. Simultaneous quantification of 17 immune mediators in aqueous humour from patients with corneal rejection. Acta Ophthalmol. Scand. 2006;84:759–765
  22. Hafler D. Multiple sclerosis. J. Clin. Invest. 2004;113:788–794
  23. Graber JJ, Ford D, Zhan M, Francis G, Panitch H, Dhib-Jalbut S. Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response. J. Neuroimmunol. 2007;185:168–174
  24. Hogancamp WE, Rodriguez M, Weinshenker BG. The epidemiology of multiple sclerosis. Mayo Clin. Proc. 1997;72:871–878
  25. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain. 1997;120:865–916
  26. Holmskov U, Thiel S, Jensenius JC. Collectins and ficolins: humoral lectins of the innate immune defense. Annu. Rev. Immunol. 2003;21:547–578
  27. Jacobs L, Johnson KP. A brief history of the use of interferons as treatment of multiple sclerosis. Arch. Neurol. 1994;51:1245–1252
  28. Koch-Henriksen N, Sørensen PS, Christensen T, Frederiksen J, Ravnborg M, Jensen K, et al. A randomized study of two interferon-beta treatments in relapsing–remitting multiple sclerosis. Neurology. 2006;66:1056–1060
  29. Kornek B, Lassmann H. Neuropathology of multiple sclerosis — new concepts. Brain Res. Bull. 2003;6:321–326
  30. Kozovska ME, Hong J, Zang YC, Li S, Rivera VM, Killian JM, et al. Interferon beta induces T-helper 2 immune deviation in MS. Neurology. 1999;53:1692–1697
  31. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–1452
  32. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med. 2001;7:115–121
  33. Lindeskog M, Mager DL, Blomberg J. Isolation of a human endogenous retroviral HERV-H element with an open env reading frame. Virology. 1999;258:441–450
  34. Mameli G, Serra C, Astone V, Castellazzi M, Poddighe L, Fainardi E, et al. Inhibition of multiple-sclerosis-associated retrovirus as biomarker of interferon therapy. J. Neurovirol. 2008;14:73–77
  35. Moller-Kristensen M, Jensenius JC, Jensen L, Thielens N, Rossi V, Arlaud G, et al. Levels of mannan-binding lectin-associated serine protease-2 in healthy individuals. J. Immunol. Methods. 2003;282:159–167
  36. Moller-Kristensen M, Thiel S, Jensenius JC. MBL polymorphisms and infectious diseases. In:  Vasta GR,  Ahmed H editor. Animal Lectins, a Functional View. Boca Raton, FL: CRC Press; 2007;Chapter 22
  37. Nicoletti F, Di Marco R, Patti F, Zaccone P, L'Episcopo MR, Reggio E, et al. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha. Cytokine. 2000;12:682–687
  38. Oh U, Yamano Y, Mora CA, Ohayon J, Bagnato F, Buttman J, et al. Interferon-β1a therapy for HTLV-I-associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) reduces HTLV-I-specific CD8+ T cells: analysis of HAM/TSP biomarkers. Ann. Neurol. 2005;57:526–534
  39. Poser CM, Paty DW, Scheinberg LC, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983;13:227–231
  40. Power C. Retroviral diseases of the nervous system: pathogenic host response or viral gene-mediated neurovirulence?. Trends Neurosci. 2001;24:162–169
  41. Rep MH, Hintzen RQ, Polman CH, van Lier RA. Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J. Neuroimmunol. 1996;67:111–118
  42. Rudick RA, Ransohoff RM, Peppler R, Vanderbrug Medendorg S, Lehmann P, Alan J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann. Neurol. 1996;40:618–627
  43. Salama HH, Kolar OJ, Zang YC, Zhang J. Effects of combination therapy of IFNbeta-1a and prednisone on serum immunologic markers in patients with multiple sclerosis. Mult. Scler. 2003;9:28–31
  44. Sellner J, Greeve I, Findling O, Kamm CP, Minten C, Engelhardt B, et al. Effect of interferon-beta and atorvastatin on Th1/Th2 cytokines in multiple sclerosis. Neurochem. Int. 2008;53:17–21
  45. Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing–remitting multiple sclerosis. Lancet. 2003;362:1184–1191
  46. Steinman L. Nuanced roles of cytokines in three major human brain disorders. Clin. Invest. 2008;118:3557–3563
  47. Stengaard-Pedersen K, Thiel S, Gadjeva M, Moller-Kristensen M, Sorensen R, Jensen LT, et al. Inherited deficiency of mannan-binding lectin-associated serine protease 2. N. Engl. J. Med. 2003;349:554–614
  48. Thiel S. Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. Mol. Immunol. 2007;44:3875–3888
  49. Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, Poulsen K, et al. A second serine protease associated with mannan-binding lectin that activates complement. Nature. 1997;386:506–510
  50. Thiel S, Holmvad SH, Dahl M, Jensenius JC. An assay for mannan-binding lectin (MBL) associated serine protease 3, MASP-3. Mol. Immunol. 2006;43:122–191
  51. Thiel S, Steffensen R, Christensen IJ, Ip WK, Lau YL, Reason IJ, et al. Deficiency of mannan-binding lectin associated serine protease-2 due to missense polymorphisms. Genes Immun. 2007;8:154–163
  52. Ulvestad E, Aarseth JH, Vedeler C, Nyland H, Myhr KM. The effects of interferon-alpha2a on concentrations of immunoglobulins, complement and lymphocytes in patients with multiple sclerosis. Scand. J. Immunol. 2004;59:103–108
  53. Vilcek J. Fifty years of interferon research: aiming at a moving target. Immunity. 2006;25:343–348
  54. Wandinger KP, Sturzebecher CS, Bielekova B, Detore G, Rosenwald A, Staudt LM, et al. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann. Neurol. 2001;50:349–357
  55. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain. 1989;112:133–146
  56. Weinstock-Guttman B, Ramanathan M, Zivadinov R. Interferon-beta treatment for relapsing multiple sclerosis. Expert Opin. Biol. Ther. 2008;8:1435–1447
  57. Wiesemann E, Deb M, Hemmer B, Radeke HH, Windhagen A. Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis. Clin. Immunol. 2008;128:306–313
  58. Xu V, Kulkovsky J, Acheampong E, Nunnari G, Sullivan J, Pomerantz RJ. HIV-1-mediated apoptosis of neuronal cells: proximal molecular mechanisms of HIV-1-induced encephalopathy. Proc. Natl. Acad. Sci. USA. 2004;101:7070–7075
  59. Ytting H, Christensen IJ, Thiel S, Jensenius JC, Svendsen MN, Nielsen L, et al. Biological variation in circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease-2 and the influence of age, gender and physical exercise. Scand. J. Immunol. 2007;66:458–464

PII: S0165-5728(09)00338-5

doi: 10.1016/j.jneuroim.2009.08.015

Journal of Neuroimmunology
Volume 215, Issue 1 , Pages 108-116 , 30 October 2009

Article Tools

* Image Usage & Resolution